Abstract
The authors wish to make the following corrections to their article: Benazzo F, Bernetti A. Rheological properties and clinical efficacy of a chemically modified hyaluronic acid for joint health enhancement. Drugs Context. 2026;15:2025-10-4.
Corrigendum
The authors regret that there are errors in their original paper.
The following shows where original text has been removed (strikethrough) and new wording introduced (underlined).
Page 4, Table 1
Table 1.
Summary of clinical evidence for Hymovis and Hymovis ONE.
| Indication | Study design | Intervention | Key outcomes | Ref. |
|---|---|---|---|---|
| Osteoarthritis | ||||
| Knee OA | Prospective multicentre (n=49) | Hymovis | ↓ WOMAC ↑ EQ-5D |
Benazzo et al. 201624 |
| Retrospective observational (n=937) | Hymovis | ↓ VAS
pain ↓ WOMAC ↓ NSAID use |
Priano 201725 | |
| Prospective cohort (n=49) | Hymovis | ↓ VAS ↓WOMAC ↑ PCS score |
Meehan et al. 202336 | |
| Prospective randomized trial (n=150) | Hymovis versus corticosteroids | ↓ WOMAC ↓ Pain ↑ Function |
Bisicchia et al. 201627 | |
| Prospective randomized trial (n=62) | Hymovis ONE versus Synvisc ONE | ↓ WOMAC | Pavelka et al. 202037 | |
| Prospective cohort (n=46) | Hymovis | ↑ MRI cartilage volume/thickness ↓ WORMS effusion ↓ Cartilage degradation biomarkers |
Henrotin et al. 201939 | |
| Shoulder OA | Prospective open label (n=41) | Hymovis | ↓ Pain ↑ ROM ↑ CS |
Porcellini et al. 201626 |
| Prospective randomized (n=80) | Hymovis versus corticosteroids | ↓ VAS ↑ ROM ↑ EQ-5D |
Di Giacomo & de Gasperis 202328 | |
| Hip OA | Real-world retrospective (n=198) | Hymovis ONE | ↓ VAS ↓ Lequesne index ↓ NSAID use |
Migliore et al. 202034 |
| Meniscal tears | ||||
| Meniscal tears | Prospective randomized (n=50) | Hymovis versus standard treatment | ↓ VAS ↑ WOMAC function ↓ Lesion size at MRI |
Zorzi et al. 201629 |
| Prospective cohort (n=40) | Hymovis | ↑ WOMAC function ↑ Quality of life ↓ T2 relaxation time |
Berton et al. 202030 | |
| Athletes | ||||
| Knee OA | Prospective observational (n=30) | Hymovis |
↓ VAS
↑ KOOS |
Tamburrino et al. 201657 |
| Knee OA | Prospective observational (n=30) | Hymovis | ↓ VAS ↑ KOOS |
Bernetti et al. 202031 |
| Hip OA | Retrospective observational (n=30) | Hymovis | ↓ VAS ↑ HAS, HAGOS |
Rando et al. 202141 |
| Knee/ankle OA | Prospective cohort (n=31) | Hymovis ONE®, 32 mg/4 mL | ↓ Pain (VAS, WOMAC-A and KOOS) ↑ KOOS function |
Bernetti et al. 202132 |
| Knee/ankle chondropathy | Prospective multicentre (n=25) | Hymovis ONE®, 32 mg/4 mL |
↓ VAS ↑ 2000 IKDC, Modified Lysholm score ↑ AOFAS score |
Perticarini et al. 2021 40 |
2000 IKDC, International Knee Documentation Committee 2000 subjective Knee; AOFAS, Foot Ankle Society ankle-hindfoot Score; CS, Constant-Murley Shoulder Outcome Score; HAGOS, Copenhagen Hip and Groin Outcome Score; HAS, Heidelberg Sports Activity Score; KOOS, Knee injury and Osteoarthritis Outcome Score; NSAID, non-steroidal anti-inflammatory; OA, osteoarthritis; PCS, physical component score; ROM, range of motion; VAS, Visual Analogue Scale; WOMAC, Western Ontario and McMaster University Osteoarthritis Index; WOMAC-A, Western Ontario and McMaster University Osteoarthritis Index; WORMS, Whole-Organ MRI Score.